Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Le Tourneau Christophe, Liem Xavier, Nguyen France, Deraedt Simon, Salas Sébastien, Calugaru Valentin, Serrahima Maria Plana, Wong Hee Kam Stéphanie, Hoffmann Caroline, Lesnik Maria, Blanchard Pierre, Poissonnet Gilles, Bozec Alexandre, Saada-Bouzid Esma, Jégoux Franck, Castelli Joël, Devisetty Kiran, Lelonge Yann, Jadaud Eric, Houdas Laetitia, Debard Anais, Vivar Omar I, Finzi Laetitia, Serra Alessandra, Linares Isabel, Arranz Obispo Carlos, Thariat Juliette, Rambeau Audrey, Fakhry Nicolas, Santini Laure, Giralt Jordi, Braña García Irene, Barba Manuel Sáez, Gorphe Philippe, Helfferich Frigyes, Herczeg Adrienn, Papai Zsuzsanna, Fijuth Jacek, Takácsi-Nagy Zoltán
Аннотация
OBJECTIVE: To evaluate safety and preliminary efficacy of NBTXR3 followed by RT in patients with locally advanced HNSCC ineligible to receive concurrent systemic therapy.
DESIGN, SETTING, AND PARTICIPANTS: This single-arm, phase 1 dose-expansion nonrandomized clinical trial was conducted across 20 centers in Europe between March 4, 2019, and January 10, 2022. Patients were ineligible for cisplatin and cetuximab per investigator's judgement and had unresectable T3-4 or overall stage III/IVA HNSCC (per the American Joint Committee on Cancer Staging Manual, eighth edition) of the oral cavity or oropharynx. Data were analyzed from July to August 2023.
INTERVENTIONS: Patients received a single intratumoral administration of NBTXR3 in the primary tumor at the recommended dose of 22% of estimated tumor volume (ETV) followed by RT (70 Gy over 35 fractions).
MAIN OUTCOMES AND MEASURES: Primary outcomes were safety and efficacy assessed by the objective response rate (ORR) of the NBTXR3-injected primary tumor. Other outcomes included ORR of all lesions (injected primary tumor and noninjected involved lymph nodes), progression-free survival, and overall survival.
RESULTS: Of the 56 patients treated, the median (range) age was 72 (44-89) years, 40 (71%) were men, 34 (61%) were 70 years and older, and 36 (64%) had a substantial burden of comorbidities (age-adjusted Charlson Comorbidity Index score of 4 or greater). Median (range) follow-up was 33.0 (0.7-44.6) months. NBTXR3-related treatment-emergent adverse events occurred in 9 patients (16%), of which 6 (11%) were grade 3 or higher, the most frequent being stomatitis (2 [4%]). Objective tumor response was assessed in 44 patients, as 12 patients were unable to complete RT or did not have posttreatment tumor assessment. In this evaluable patient population, the ORR of the injected primary tumor and ORR of all lesions were 82% (95% CI, 67-92) and 80% (95% CI, 65-90), respectively. Among all 56 treated patients, the median progression-free survival was 11.4 months (95% CI, 6.7 to not reached), and the median overall survival was 18.1 months (95% CI, 9.7 to not reached).
CONCLUSIONS AND RELEVANCE: This dose-expansion phase 1 nonrandomized clinical trial demonstrated that intratumoral NBTXR3 followed by RT in a high-risk patient population unable to receive cisplatin or cetuximab was feasible and had a preliminary efficacy signal that supports a benefit-risk profile being evaluated in an ongoing randomized phase III trial.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01946867.